capecitabine

Type: Keyphrase
Name: capecitabine
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Onyx and Bayer's Phase III breast cancer trial fails to meet primary endpoint

Onyx Pharmaceuticals Inc., a biopharmaceutical company, and Bayer HealthCare have announced that an investigational Phase III trial of NEXAVAR tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free ... [Published Individual.com - 20 hours ago]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Breast carcinoma with choriocarcinomatous features: a case report and review of the literature

Breast carcinoma with choriocarcinomatous features (BCCF) is a rare variant of breast cancer, characterized by high expression of human chorionic gonadotropin (HCG) in cancer cells such as multinucleated syncytiotrophoblast-like giant cells. The first ... [Published 7thSpace - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Forum Post: Chemo, PICC line with DVT?

For everything about chemotherapy, being treated and side effects. Tell others about your experiences and get answers to your questions.Chemo, PICC line with DVT?Posted by DeusEx on28 Jul 2014 11:10 PMSo, it looks like my cancer (pseudomyxoma) has recurred ... [Published Macmillan Cancer Support - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 2 reports

Bayer Onyx report results from Phase III breast cancer trial of sorafenib

Related Biotechnology, Pharmaceutical and Healthcare NewsBayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have released results from an investigational Phase III trial of sorafenib (Nexavar) tablets plus capecitabine in patients with advanced ... [Published BioPortfolio - Jul 28 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Nexavar fails to meet primary endpoint in HER-2–negative breast cancer

Results from a phase 3 trial have found that sorafenib plus capecitabine did not meet its primary endpoint of improving PFS for the treatment of locally advanced or metastatic HER-2–negative breast cancer, manufacturers Bayer HealthCare Pharmaceuticals ... [Published Orthopedics Today - Jul 26 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Rilotumumab Added to First-Line Chemotherapy May Benefit Patients With Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Figures:Timothy Iveson, MDRilotumumab plus ECX had no unexpected safety signals and showed greater activity than placebo plus ECX. A phase 3 study of the combination in MET-positive gastric and oesophagogastric junction cancer is in progress.—Timothy ... [Published The ASCO Post - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

“I couldn’t believe how much things had moved on” – Nicola’s story

“I went into a bit of a practical mode: this is what we need to do, everything will be fine. They sent me for further tests to see how far the cancer had spread and that’s when I found out it was much worse than we initially thought.“That’s when the reality ... [Published Cancer Research UK - Jul 23 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

Forum Post: Appendix Cancer Experience

> Cancer types> Bowel (colon & rectum) cancer> Bowel (Colon & Rectum) Cancer Group - Discussion Forum> Appendix Cancer ExperienceDiscussion toolsKeywordsAppendix Cancer ExperienceBowel (colon & rectum) cancerA group for anyone affected by ... [Published Macmillan Cancer Support - Jul 19 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 1 reports

T-DM1 Poised to Set New Standard in HER2-Positive Metastatic Breast Cancer

Adam Brufsky, MD, PhDThe antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) will have an impact on the entire spectrum of care for patients with metastatic HER2-positive breast cancer, resulting in a greater emphasis on patient selection ... [Published OncLive - Jul 14 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Halaven (eribulin) Garners European Commission MAA for Advanced Breast Cancer After Only One Prior Chemotherapy

The European Commission (EC) has issued Marketing Authorisation Approval (MAA) for Halaven (eribulin) in the treatment of patients with locally advanced or metastatic breast cancer (MBC) who have progressed after at least one chemotherapeutic regimen ... [Published Individual.com - Jul 08 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Life-extending treatment for metastatic breast cancer now licenced in UK after one prior chemotherapy

Current ratings for: Ratings require JavaScript to be enabled.From 3 July 2014, Halaven® (eribulin) is licenced in the UK for the treatment of patients with locally advanced or metastatic breast cancer (MBC) who have progressed after at least one chemotherapeutic ... [Published Medical News Today - Jul 04 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 2 reports

Eribulin receives European commission marketing authorisation approval for advanced breast cancer after only one prior chemotherapy

The European Commission (EC) has issued Marketing Authorisation Approval (MAA) for eribulin in the treatment of patients with locally advanced or metastatic breast cancer (MBC) who have progressed after at least one chemotherapeutic regimen for advanced ... [Published Ecancer Medicalscience - Jul 03 2014]

Quotes

...in patients with advanced breast cancer," said Dr Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development. "While the primary endpoint of this trial was not met, the trial results do not affect the currently approved indications for NEXAVAR. We would like to thank the patients and the study investigators for their contributions and participation in this study."
...end of the second quarter, 132 patients had started receiving commercial VIMIZIM," said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin.  "Since receiving approval of VIMIZIM in the European Union in April, we are making good progress seeking reimbursement on a country by country basis. The excitement we are seeing in the Morquio community is driving our expectation of continued, rapid uptake of VIMIZIM across all our commercial markets. With E U approval in hand, we believe VIMIZIM sales combined with the strength of our other marketed products will help BioMarin reach over $1 billion in revenues over the next 2-3 years."
NEXT ARTICLE More From BioPortfolio on "Bayer, Onyx report results from Phase III breast cancer trial of sorafenib"
...(35 percent vs 4 percent), leukopenia (31 percent vs 10 percent), diarrhoea (14 vs 29 percent) and nausea (22 percent vs 24 percent), respectively. "Eisai is very pleased that eribulin is now indicated for use in women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. This earlier use of eribulin will allow more women across Europe to receive the survival benefits that treatment with eribulin may provide. As a company, we continue to be committed to broadening access to eribulin to help redress the inequality between early and advanced breast cancer outcomes" said Gary Hendler, President Eisai Global Oncology Business Unit

More Content

All (100) | News (83) | Reports (0) | Blogs (17) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Onyx and Bayer's Phase III breast cancer trial ... [Published Individual.com - 20 hours ago]
Teva Pharmaceutical Industries' (TEVA) CEO Erez... [Published Seeking Alpha - Jul 31 2014]
Incyte's (INCY) CEO Hervé Hoppenot on Q2 2014 R... [Published Seeking Alpha - Jul 31 2014]
BioMarin Announces Second Quarter 2014 Financia... [Published Myrtle Beach Sun News - Jul 30 2014]
Breast carcinoma with choriocarcinomatous featu... [Published 7thSpace - Jul 30 2014]
Forum Post: Chemo, PICC line with DVT? [Published Macmillan Cancer Support - Jul 28 2014]
Bayer Onyx report results from Phase III breast... [Published BioPortfolio - Jul 28 2014]
Bayer, Onyx report results from Phase III breas... [Published PBR - News - Jul 28 2014]
Nexavar fails to meet primary endpoint in HER-2... [Published Orthopedics Today - Jul 26 2014]
Promising Cancer Drug Fails to Slow Breast Cancer [Published Austin American Statesman - Jul 25 2014]
Promising Cancer Drug Fails to Slow Breast Cancer [Published Time - Jul 25 2014]
Promising Cancer Drug Fails to Slow Breast Cancer [Published TIME.com - Jul 25 2014]
Sorafenib/Capecitabine Combo Fails to Meet Prim... [Published P&T Community - Jul 25 2014]
Bayer/Amgen's Nexavar Does Not Show Resilience ... [Published Zacks.com - Jul 25 2014]
Sorafenib-Capecitabine Combination Fails Phase ... [Published Genetic Engineering News - Jul 25 2014]
Phase III Trial of Sorafenib in Combination wit... [Published Bayer HealthCare - Jul 25 2014]
Bayer/Amgen breast cancer drug fails to delay d... [Published MedCity News - Jul 25 2014]
Sorafenib, Capecitabine Combo Fails to Meet End... [Published Drug Discovery and Development - Jul 25 2014]
Bayer and Onyx report disappointing Phase III r... [Published Pharma Letter - Jul 25 2014]
Phase III Trial of Sorafenib in Combination wit... [Published PipelineReview - Jul 25 2014]
Nexavar fails late-stage breast cancer trial [Published PMLive - Jul 25 2014]
Phase III Trial of Sorafenib in Combination wit... [Published Bayer - Jul 25 2014]
Phase 3 trial: NEXAVAR tablets fail to meet pri... [Published News-Medical.Net - Jul 25 2014]
Bayer, Amgen's Nexavar fails to hit main goal i... [Published FirstWord Pharma - Jul 25 2014]
Bayer/Amgen's Nexavar fails in breast cancer trial [Published Pharma Times - Jul 25 2014]
BAYER : and Onyx Say Phase III Trial of Nexavar... [Published 4 Traders - Jul 25 2014]
Bayer says Nexavar fails in breast cancer study [Published Reuters UK - Jul 25 2014]
BRIEF-Bayer says phase III trial of Sorafenib d... [Published Reuters UK - Jul 25 2014]
Bayer, Onyx Pharma Say Phase 3 Trial Of NEXAVAR... [Published RTTNews.com - Jul 25 2014]
Phase III Trial of Sorafenib in Combination wit... [Published Bayer Corporate News - Jul 25 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Bayer, Onyx report results from Phase III breas... [Published PBR - News - Jul 28 2014]
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have released results from an investigational Phase III trial of sorafenib (Nexavar) tablets plus capecitabine in patients with advanced breast cancer. ...
Promising Cancer Drug Fails to Slow Breast Cancer [Published TIME.com - Jul 25 2014]
A Phase 3 trial of cancer drug Nexavar in patients with advanced breast cancer failed to delay progression of the disease, according to the drug’s makers, Bayer and Onyx Pharmaceuticals, Inc., an Amgen subsidiary. The study, called Reslience, evaluated ...
Phase III Trial of Sorafenib in Combination wit... [Published Bayer Corporate News - Jul 25 2014]
The false hope of “right-to-try” metastasizes t... [Published Science-Based Medicine - Jul 21 2014]
Ed. note: Please read disclaimer in Dr. Gorski’s profile ! There are times when supporting science-based health policy and opposing health policies that sound compassionate but are not are easily portrayed as though I’m opposing mom, apple pie, ...
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
There’s a point I feel that I have have to make briefly as I begin this post. Basically, this might look familiar, but given that I was at TAM Wednesday through Sunday, I didn’t have time to produce two separate posts, and this is important enough ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.